Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spon...

por Poddubnyy, Denis, Hammel, Ludwig, Heyne, Marvin, Veit, Justyna, Jentzsch, Claudia, Baraliakos, Xenofon
Publicado 2020

Drug switching in axial spondyloarthritis patients in Germany – a social listening analysis

por Kahn, Maria, Papukchieva, Steffeni, Fehr, Axel, Eberl, Markus, Rösler, Berenice, Veit, Justyna, Friedrich, Benjamin, Poddubnyy, Denis
Publicado 2023

Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study

por Kiltz, Uta, Sfikakis, Petros P., Gaffney, Karl, Sator, Paul-Gunther, von Kiedrowski, Ralph, Bounas, Andreas, Gullick, Nicola, Conrad, Curdin, Rigopoulos, Dimitris, Lespessailles, Eric, Romanelli, Marco, Ghislain, Pierre-Dominique, Brandt-Jürgens, Jan, Rashkov, Rasho, Aassi, Maher, Orsenigo, Roberto, Perella, Chiara, Pournara, Effie, Gathmann, Sven, Jagiello, Piotr, Veit, Justyna, Augustin, Matthias
Publicado 2020